ERBB2 and breast cancer: The results showed that the prognostic value of GPS1 was significant in Luminal B breast cancer, and the prognosis was worse in those with high expression of GPS1 (p < 0.01), whereas no significant prognostic significance was found in Luminal A, Basal-like, and HER2 + breast cancers (Fig. 6A).